1142223-08-2Relevant articles and documents
Design and Synthesis of Novel, Selective GPR40 AgoPAMs
Plummer, Christopher W.,Clements, Matthew J.,Chen, Helen,Rajagopalan, Murali,Josien, Hubert,Hagmann, William K.,Miller, Michael,Trujillo, Maria E.,Kirkland, Melissa,Kosinski, Daniel,Mane, Joel,Pachanski, Michele,Cheewatrakoolpong, Boonlert,Nolting, Andrew F.,Orr, Robert,Christensen, Melodie,Campeau, Louis-Charles,Wright, Michael J.,Bugianesi, Randal,Souza, Sarah,Zhang, Xiaoping,Di Salvo, Jerry,Weinglass, Adam B.,Tschirret-Guth, Richard,Nargund, Ravi,Howard, Andrew D.,Colletti, Steven L.
supporting information, p. 221 - 226 (2017/03/08)
GPR40 is a G-protein-coupled receptor expressed primarily in pancreatic islets and intestinal L-cells that has been a target of significant recent therapeutic interest for type II diabetes. Activation of GPR40 by partial agonists elicits insulin secretion
Discovery of AM-1638: A potent and orally bioavailable GPR40/FFA1 full agonist
Brown, Sean P.,Dransfield, Paul J.,Vimolratana, Marc,Jiao, Xianyun,Zhu, Liusheng,Pattaropong, Vatee,Sun, Ying,Liu, Jinqian,Luo, Jian,Zhang, Jane,Wong, Simon,Zhuang, Run,Guo, Qi,Li, Frank,Medina, Julio C.,Swaminath, Gayathri,Lin, Daniel C.-H.,Houze, Jonathan B.
, p. 726 - 730 (2012/10/30)
GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets, the activation of which elicits increased insulin secretion only in the presence of elevated glucose levels. A potent, orally bioavailable small molecule GPR40 agonist
